Everolimus is an orally administered inhibitor of the mammalian target of rapamycin (mTOR) and used in breast cancer, some neuroendocrine tumors, and renal cell carcinoma (RCC) as an antineoplastic agent. This evidence concerns the gene MTOR and hereditary clear cell renal cell carcinoma.